写意报告 | 国家癌症中心李宁：CGT药物创新与临床开发的风险与机遇
本文系李宁在“2024同写意CGT产业大会”上做的报告内容整理。
Time：
2024-09-04 09:08
Author：
xieyijun
Recommended content
WCLC 2026 | Hansun "Blows the Roof Off", the New King of B7-H3 ADC is About to be Crowned
It's time for Chinese innovative drugs to redefine the standards.
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务